Published in Cancer Weekly, November 22nd, 1999
This is the use of genetic information to develop new anticancer therapies to treat specific patient populations or tumor types, or to tailor existing therapies to individual patients. Bristol-Myers Squibb is collaborating with MPMx to apply this research approach to some of Bristol-Myers Squibb's oncology drugs in development and to marketed products.
The Bristol-Myers Squibb/MPMx collaboration is the first integrated application...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.